Led · Series A · Jul 2021

neuro42 develops portable MRI systems and robotic intervention technology to enable bedside neuroimaging and interventions. Its compact Diagnostic MRI scanner is FDA 510(k) cleared for neuroimaging and is designed to enable rapid diagnosis at the patient’s bedside. The company has also built a robotic interventional module aimed at improving procedures such as brain biopsies and ablations. neuro42 is seeking regulatory clearance for its interventional module. Led by CEO and Founder Dr. Amit Vohra and based in San Francisco, the company intends to use new capital to accelerate development and bring solutions to patients. It recently received an investment from Zynext Ventures (amount undisclosed) to support that progress. neuro42 is a San Francisco-based medical technology company developing and commercializing an intraoperative MRI, artificial intelligence, and robotic platform for brain imaging and image-guided surgical interventions. The company is developing a first-of-its-kind MRI and robot that enables physicians to diagnose brain injury in acute settings and perform intraoperative treatments under live imaging. Its novel scanner allows robotic procedures outside the traditional magnetic resonance suite, expanding possibilities for intraoperative image guidance and disease treatment. neuro42's platform is portable, patient-centric, backed by over 30 patents, and targets conditions including stroke, hydrocephalus, epilepsy, and various brain tumors. The company intends to use financing to advance product development and scale deployment to physicians and neurosurgeons. To date the company has raised $7.8M, including an oversubscribed $1.3M seed round earlier this year and a recent $6.5M Series A.

Participated · Series D · Feb 2021

Hyperfine develops portable MRI systems designed to enable brain imaging at the bedside and in outpatient settings. The company is focused on expanding sales beyond hospital critical care into neurology offices and international markets while continuing to invest in software development and clinical studies to support broader adoption. Hyperfine reported $13.6 million in revenue for 2025, a 5.2% increase year over year, including $5.3 million in fourth-quarter revenue which more than doubled year over year. Despite revenue growth, the company posted a net loss of about $35.6 million for 2025 and ended the year with roughly $35 million in unrestricted cash. Hyperfine reduced its global workforce in January 2025 by about 14% and had 102 employees as of Feb. 15, 2026, down from 111 a year earlier.

Led · Equity · Jan 2021

Promaxo is an Oakland, CA–based company that develops portable low-field MRI systems and minimally invasive robotics aimed at improving medical imaging and interventions. Its open, compact MRI has a limited fringe field so it can be placed in clinics or operating rooms and is designed to be compatible with robotic procedures. The Promaxo system enables earlier diagnosis and treatment in a wider range of healthcare settings and is the first in the U.S. to receive FDA 510(k) clearance for prostate biopsy and treatment. Led by Founder and CEO Dr. Amit Vohra, the company is building a minimally invasive, patient-centric MRI and robotic platform that incorporates imaging, robotics and AI capabilities. Promaxo is currently working to obtain FDA clearance for its own robot to further enhance precision and predictability in prostate interventions. Promaxo develops a minimally-invasive, patient-centric MRI and robotic platform for point-of-care diagnostic biopsies and cancer treatment. The company, based in Oakland, California, holds over 200 patents and emphasizes state-of-the-art medical imaging, robotics, and AI capabilities. Promaxo is commercializing a compact and adaptable MRI system and has formed numerous long-term and strategic partnerships with investor groups and corporations. To support continued commercialization and sales, Promaxo announced an upsized asset financing agreement with kineo finance that increases its direct leasing solution. The expanded agreement is intended to support the company’s commercial and customer sales programs and to cover its expected sales pipeline in 2023. Kineo finance is a Swiss-headquartered asset financing group with subsidiaries in the USA and Germany that provides venture leasing and working capital solutions and is backed by institutional investors. Promaxo develops a compact, adaptable MRI and robotic platform intended to enable safe, effective point-of-care diagnostic biopsies and to facilitate cancer treatment through an open architecture. The company emphasizes a minimally-invasive, patient-centric approach and integrates imaging, robotics and AI capabilities. Promaxo says its system overcomes limitations of traditional MRI systems and has received favorable physician feedback. Management highlights a large addressable market, citing a $3 billion market for prostate cancer. The company is based in Oakland, California, was founded by entrepreneurs and healthcare innovators, and is backed by over 200 patents. Promaxo has formed numerous long-term and strategic partnerships as it drives commercialization of its in-office MRI system. Promaxo develops a minimally‑invasive, patient‑centric MRI and robotic platform that combines medical imaging, robotics and AI for point‑of‑care diagnostic biopsies and cancer interventions. The company offers a compact, adaptable MRI system intended to improve the quality and speed of patient diagnosis and procedures. Promaxo is backed by over 90 patents and has formed numerous long‑term and strategic partnerships with investor groups and corporations as it prepares to enter the US market. Management says the platform targets in‑office diagnostic and therapeutic procedures, including a cited $3 billion addressable market for in‑office urology procedures. To expand commercial adoption, Promaxo is adding direct leasing and sales‑and‑lease‑back options for physician practices and academic centers. An asset financing agreement with kineo finance is intended to support these growth initiatives and broaden market penetration of its platform technology. Promaxo develops a minimally-invasive, patient-centric MRI and robotic platform centered on a compact and adaptable MRI system. The company emphasizes incorporation of artificial intelligence into imaging and image-based interventions and holds over 60 patents. Promaxo says its technology aims to improve the quality and speed of patient screening and interventions and to redefine the standard of care. The firm plans to use recent funding to accelerate its data strategy and further integrate AI capabilities. Promaxo has formed numerous long-term and strategic partnerships as it prepares to enter the U.S. market and is based in Oakland, California. Leadership describes a goal of introducing a truly open MRI system to the masses and expanding the frontiers of medical imaging, robotics, and AI.

Led · Series D · Jun 2019

SiFive develops CPUs based on the open-source RISC-V instruction set aimed at large data center operators and hyperscalers. The company plans to offer rapidly customizable CPU solutions intended as alternatives to prevalent Nvidia AI accelerators and Arm-based server chips. SiFive intends to expand its software ecosystem to support its hardware offerings. In the funding announcement, SiFive said it will use newly raised capital to accelerate product and software development for AI data centers. The competitive landscape cited research estimating roughly 135 companies are developing or planning AI processors, with only about 25 expected to survive by 2030. SiFive's recent $400 million funding round values the company at $3.65 billion, reflecting its current financial backing.

Led · Series A · Feb 2019

GreenWaves develops the GAP8 family, an ultra-low-power RISC-V / PULP parallel processor for on-device machine learning inference in battery-operated edge devices. GAP8 targets IoT and consumer battery-operated applications including wearables, people and object counting, machine health monitoring, home surveillance, voice control, face detection and recognition, consumer robotics, micro-drones and smart toys. The processor emphasizes leading energy efficiency, ultra-fast wake up, low standby power and dynamically adjustable frequency and voltage. GAP8 was launched in February 2018; more than 300 development boards have been sold and the company reports multiple customer designs in progress. GreenWaves positions itself as an early RISC-V silicon vendor with a differentiated technical and market approach. The company is developing a second-generation product to provide a quantitative and qualitative leap in capabilities for intelligent, battery-powered edge devices. GreenWaves Technologies designs ultra-low-power embedded processors and software to run image, audio and vibration AI on battery-operated sensing devices. Its flagship product, GAP8, is a RISC-V–based IoT application processor featuring an 8-core computational cluster, a convolution hardware accelerator and a separate core in an independent voltage/frequency domain for communication and control. GAP8 is optimized for energy-efficient CNN inference and a wide spectrum of image and audio algorithms, enabling use cases such as always-on face detection, people counting, machine health monitoring, speech recognition and low-cost machine vision. The company provides a GAP8 Software Development Kit and guided toolchain to port trained CNNs and offers evaluation boards for pre-order; a development board rollout was planned for April 2018. GreenWaves builds on the open-source PULP and RISC-V projects and emphasizes capital-efficient engineering to speed time to market. The company was founded in 2014 and is headquartered just outside Grenoble, France.